Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Retinal Biologics Market Evolve in Terms of Growth and Size by 2029?

In recent times, there has been a significant expansion in the size of the retinal biologics market. The market, valued at $25.17 billion in 2024, is forecasted to reach $28.12 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.7%. This growth during the historic period is primarily due to the rising prevalence of retinal disorders, an aging global population, growing consciousness and early disease detection, advancements in healthcare infrastructure, and an increase in healthcare spending.

Expectations are high for substantial growth in the retinal biologics market size in the upcoming years. Predictions show it will reach $43.55 billion in 2029, rising at a compound annual growth rate (CAGR) of 11.6%. The projected growth during the forecast period is due to factors such as increasing therapeutic applications, the rise of personalized medicine, growth in emerging markets, a robust biologics pipeline, collaborations and partnerships, and government initiatives and support. The major developments to watch during this forecast period include non-invasive delivery methods, utilization of real-world evidence, an expansion of indications, regulatory pathway streamlining, and a focus on patient-centric outcomes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

What factors are expected to fuel Retinal Biologics market growth in the coming years?

The forecasted expansion of the retinal biologics market is attributed to the escalating occurrence of diabetic eye disease. As a consequence of diabetes, this disorder impairs the eyes, resulting in vision impairment and blindness among those diagnosed. Retinal biologics offer hope for more precise and successful treatments, providing early intervention and enhanced results to prevent vision loss linked to diabetic eye disease. For example, data from the Australian Bureau of Statistics in December 2023 revealed that, in 2022, diabetes affected 5.3% of the Australian population, equating to around 1.3 million individuals. This represented a significant surge from the previous 3.3%. Consequently, the escalating rate of diabetic eye disease is propelling the retinal biologics market’s expansion.

What Are The Key Findings From The Segmentation Analysis Of The Retinal Biologics Market?

The retinal biologics market covered in this report is segmented –

1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors

2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins

Which Trends Are Expected To Shape The Future Of The Retinal Biologics Market?

The prominent players in the pruritus therapeutics market are concentrating on creating specialized treatments for specific patient demographics and rare diseases, such as the non-systemic ileal bile acid transport inhibitor which aims to provide personal, customized medicine addressing unresolved medical requirements. This specific medication targets the absorption of bile acid in the intestines without substantially impacting the systemic circulation, hence limiting potential negative effects. For example, in June 2023, Ipsen, a pharmaceutical company based in France, obtained approval from the Food and Drug Administration (FDA), a U.S based federal agency under the Department of Health and Human Services, for their medication Bylvay (odevixibat). It is used to treat cholestatic pruritus in ALGS patients who are 12 months old and above. Bylvay, an IBATi, is a daily drug with limited systemic exposure and is the first ever medication approved for progressive familial intrahepatic cholestasis (PFIC)-related cholestatic pruritus in the United States. Prior to this, it had been accepted for PFIC treatment in Europe and can currently be prescribed for eligible ALGS patients.

What Are The Most Active Companies In The Retinal Biologics Market Today?

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

Which Regional Markets Are Attracting The Most Investment In Retinal Biologics?

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model